# CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

> **NCT04702841** · EARLY_PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 8 (estimated)

## Conditions studied

- CAR
- Malignant Tumors

## Interventions

- **DRUG:** Chimeric antigen receptor modified γδ T cells

## Key facts

- **NCT ID:** NCT04702841
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-03
- **Primary completion:** 2022-06
- **Final completion:** 2022-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2021-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702841, "CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04702841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*